Nebulized furosemide in infants with bronchopulmonary dysplasia

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease in preterm infants.
• Mechanical ventilation is often required for infants with BPD, leading to potential lung injury.
• Pharmacological interventions are explored to improve respiratory outcomes in BPD.

Purpose of the Study:

• To evaluate the effects of nebulized furosemide on pulmonary functions in preterm infants with BPD.
• To determine the optimal dose of nebulized furosemide for improving lung mechanics.
• To assess the safety and duration of action of nebulized furosemide in this population.

Main Methods:

• Eight preterm infants with BPD on mechanical ventilation participated.
• Nebulized furosemide was administered at doses of 0.1, 0.25, 0.50, and 1.0 mg/kg.
• Pulmonary functions, including lung compliance, pulmonary resistance, and tidal volume, were measured.

Main Results:

• The 1.0 mg/kg dose significantly improved lung compliance by 51% at 2 hours.
• Pulmonary resistance decreased by 28% at 1 hour, and tidal volume increased by 43% at 1 hour.
• Improvements were observed as early as 30 minutes and lasted for at least 4 hours, with no diuresis or renal side effects.

Conclusions:

• Nebulized furosemide, particularly at 1.0 mg/kg, is an effective treatment for improving pulmonary functions in preterm infants with BPD.
• This intervention offers a promising therapeutic option for managing respiratory distress in this vulnerable population.
• The observed benefits were achieved without significant adverse renal or systemic effects.